CL2022002642A1 - Medicamentos para fibrosis pulmonar que contienen derivado de pirazol - Google Patents

Medicamentos para fibrosis pulmonar que contienen derivado de pirazol

Info

Publication number
CL2022002642A1
CL2022002642A1 CL2022002642A CL2022002642A CL2022002642A1 CL 2022002642 A1 CL2022002642 A1 CL 2022002642A1 CL 2022002642 A CL2022002642 A CL 2022002642A CL 2022002642 A CL2022002642 A CL 2022002642A CL 2022002642 A1 CL2022002642 A1 CL 2022002642A1
Authority
CL
Chile
Prior art keywords
pulmonary fibrosis
drugs
pyrazole derivative
containing pyrazole
fibrosis containing
Prior art date
Application number
CL2022002642A
Other languages
English (en)
Spanish (es)
Inventor
Jin Lee Soo
Hwan Moon Sung
Yu Hyunkyung
Goh Yoo-Kyung
Original Assignee
Aptabio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020210036863A external-priority patent/KR102386097B1/ko
Application filed by Aptabio Therapeutics Inc filed Critical Aptabio Therapeutics Inc
Publication of CL2022002642A1 publication Critical patent/CL2022002642A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2022002642A 2020-04-13 2022-09-27 Medicamentos para fibrosis pulmonar que contienen derivado de pirazol CL2022002642A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200044598 2020-04-13
KR1020210036863A KR102386097B1 (ko) 2020-04-13 2021-03-22 피라졸 유도체의 폐섬유증 치료제

Publications (1)

Publication Number Publication Date
CL2022002642A1 true CL2022002642A1 (es) 2023-06-16

Family

ID=78083982

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002642A CL2022002642A1 (es) 2020-04-13 2022-09-27 Medicamentos para fibrosis pulmonar que contienen derivado de pirazol

Country Status (12)

Country Link
US (1) US12616684B2 (cg-RX-API-DMAC7.html)
EP (1) EP4137134A4 (cg-RX-API-DMAC7.html)
JP (1) JP7539485B2 (cg-RX-API-DMAC7.html)
KR (2) KR102567012B1 (cg-RX-API-DMAC7.html)
CN (1) CN115427039B (cg-RX-API-DMAC7.html)
AU (1) AU2021255160B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022020649A2 (cg-RX-API-DMAC7.html)
CA (1) CA3172596A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002642A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022014273A2 (cg-RX-API-DMAC7.html)
MX (1) MX2022012726A (cg-RX-API-DMAC7.html)
WO (1) WO2021210799A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12649741B2 (en) 2021-03-22 2026-06-09 Neurocrine Biosciences, Inc. Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040094464A (ko) * 2003-05-02 2004-11-10 학교법인 이화학당 피리디닐 피라졸 유도체
RU2012110580A (ru) 2009-08-21 2013-09-27 Джилид Байолоджикс, Инк. Способы скрининга in vivo
KR101280160B1 (ko) 2009-09-02 2013-06-28 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
KR101302315B1 (ko) * 2011-07-19 2013-08-30 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 호흡기 질환 예방 및 치료용 조성물
KR101633957B1 (ko) * 2012-08-27 2016-06-27 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물
WO2015195684A2 (en) * 2014-06-16 2015-12-23 University Of Rochester Small molecule anti-scarring agents
EP3411045A4 (en) * 2016-02-02 2020-01-08 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Chemicals and methods to prevent and treat tgf-beta mediated activation of fibroblasts to reduce and treat cancer and fibrosis
WO2017192304A1 (en) 2016-05-02 2017-11-09 Inception 1, Inc. Arylcarboxamides and uses thereof
EP3573614B1 (en) 2017-01-27 2024-11-20 Genfit Pharmaceutical compositions for combination therapy
KR101821593B1 (ko) * 2017-02-23 2018-01-25 압타바이오 주식회사 안질환 치료제
SG11201907673YA (en) 2017-03-13 2019-09-27 Genfit Pharmaceutical compositions for combination therapy
CA3058542A1 (en) 2017-04-18 2018-10-25 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
KR101856444B1 (ko) 2017-04-20 2018-05-10 압타바이오 주식회사 3-페닐-4-프로필-1-(피리딘-2-일)-1h-피라졸-5-올 염산염의 신규 결정형 고체 화합물
KR101840702B1 (ko) * 2017-11-01 2018-03-22 압타바이오 주식회사 간질환 치료제
KR20210036863A (ko) 2018-08-01 2021-04-05 니폰 가야꾸 가부시끼가이샤 N-알킬기를 갖는 방향족 아민 수지, 경화성 수지 조성물 및 그 경화물
EP3628669A1 (en) * 2018-09-28 2020-04-01 GenKyoTex Suisse SA Novel compounds as nadph oxidase inhibitors
KR102207340B1 (ko) 2018-10-19 2021-01-22 한남대학교 산학협력단 표면 개질된 다공성 탄소복합소재 및 그 제조방법
CN109912600B (zh) * 2019-02-22 2021-08-03 四川大学华西医院 一种防治肺纤维化的咪唑并嘧啶类衍生物及其应用
AU2021253243B2 (en) 2020-04-08 2024-01-18 Aptabio Therapeutics Inc. Agent for treating contrast-induced acute kidney injury
WO2021263281A2 (en) * 2020-06-26 2021-12-30 Ann And Robert H. Lurie Children's Hospital Of Chicago Methods and compositions for the treatment of covid-19 and associated respiratory distress and multi-organ failure, sepsis, acute respiratory distress syndrome, and cordiovascular diseases
UY39671A (es) 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12649741B2 (en) 2021-03-22 2026-06-09 Neurocrine Biosciences, Inc. Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors

Also Published As

Publication number Publication date
MX2022012726A (es) 2022-11-07
KR20220039687A (ko) 2022-03-29
KR20210146871A (ko) 2021-12-06
BR112022020649A2 (pt) 2022-11-29
AU2021255160B2 (en) 2024-02-01
JP2023522628A (ja) 2023-05-31
US12616684B2 (en) 2026-05-05
CO2022014273A2 (es) 2022-10-21
CA3172596A1 (en) 2021-10-21
AU2021255160A1 (en) 2022-10-06
CN115427039A (zh) 2022-12-02
EP4137134A1 (en) 2023-02-22
US20230148365A1 (en) 2023-05-11
CN115427039B (zh) 2025-04-04
JP7539485B2 (ja) 2024-08-23
EP4137134A4 (en) 2024-08-07
WO2021210799A1 (ko) 2021-10-21
KR102567012B1 (ko) 2023-08-14

Similar Documents

Publication Publication Date Title
CR20220281A (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
ECSP22071009A (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
PY2240956A (es) Nuevos Compuestos bicíclicos y sus usos
CO2026005655A2 (es) Inhibidor de pan-kras y uso del mismo en medicinas
MX2021011606A (es) Compuestos dirigidos a prmt5.
CL2022003360A1 (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados (divisional de la solicitud 202002578)
DOP2022000076A (es) Inhibidores del factor d del complemento para administración oral
UY37941A (es) Derivados de bencimidazol y sus usos
CL2023000200A1 (es) Nuevo derivado de pirazol
AR132764A1 (es) Inhibidores de tyk2 y sus usos
CL2022002641A1 (es) Agente para el tratamiento de lesión renal aguda inducida por medio de contraste
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
AR133249A1 (es) Nuevos compuestos
AR126892A1 (es) Compuestos de aminopiridina sustituidos como inhibidores de egfr
MX2025008259A (es) Inhibidores de prmt5-mta
CO2022014273A2 (es) Medicamentos para fibrosis pulmonar que contienen derivado de pirazol
CO2022008209A2 (es) Compuesto que funciona como inhibidor de la quinasa del receptor de pdgf y composición
WO2020128816A3 (en) Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
MX2022016497A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento, mejora o prevencion de la enfermedad fibrotica.
CU20200102A7 (es) Compuestos derivados de isoindolin-1,2,4-triazol-3-carbonitrilo útiles para el tratamiento de enfermedades cinetoplastídicas
MX2020011367A (es) Compuesto oxo-sustituido.
AR131735A1 (es) Agentes terapéuticos
AR126552A1 (es) Composición farmacéutica para prevenir o tratar la esclerosis sistémica
UY37745A (es) Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias